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A 21 year old MSM patient with newly diagnosed HIV infection was hospitalized in our department after ingestion
of an overdose of his antiretroviral therapy (ART) comprising dolutegravir (DTG - Tivicay®) and tenofovir disaproxil
fumarate/emtricitabine (Truvada®) in suicidal intention. On admission, the patient did not show any clinical signs of
intoxication and laboratory findings were unremarkable. After 6 hours of intensive care monitoring, the patient was
referred to a psychiatric clinic. 5 days after the day of intoxication, serum creatinine levels increased to high normal
values (1.2 mg/dl). However, levels never exceeded the upper threshold. 8 and 12 weeks later, serum creatinine
normalized to levels measured prior to the intoxication. No other adverse events occurred, and the patient does
not suffer from permanent impairments.
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Antiretroviral therapy is employed in HIV patients to
achieve durable suppression of HIV replication, thereby
controlling HIV RNA, to restore immune function and
to reduce morbidity and mortality, to improve quality of
life, as well as to limit the likelihood of viral resistance
and reduce the risk of viral transmission [1-3]. Dolute-
gravir (DTG) is a novel second-generation integrase in-
hibitor and has recently been introduced for use as
antiretroviral therapy of HIV infection [4]. Recom-
mended dose for treatment of therapy-naïve patients is
50 mg per day. DTG is known to be an inhibitor of the
renal transport protein organic cation transporter 2
(OCT2), resulting in a reversible elevation of serum cre-
atinine [5]. Furthermore, inhibition of the OCT2 can result
in relevant drug interactions, e.g. dofetilide, metformin, ci-
metidine, triamterene, and procainamide [6].* Correspondence: Marcel.lee@tum.de; christoph.spinner@tum.de
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We report a 21-year old MSM patient who was admitted
to our department on June 2014 following an overdose
of antiretroviral medication (ART) in suicidal intention.
HIV-infection was diagnosed 3 weeks prior to his admis-
sion to our department.
CDC-stage of the HIV infection at primary diagnosis
was A1, WHO stage I with a documented CD4-nadir of
590/μL (norm: 490 – 1760/μl), CD4/CD8 ratio of 0.7
(norm 1.0 – 5.8) and an HIV load of 42.400 cps/ml. HIV
diagnostic was performed because of a syphilis stage II
infection with a generalized rash, a couple of weeks before.
The syphilis infection was treated with doxycycline
200 mg per day for 14 weeks and due to incomplete
decrease of VDRL titers followed by intramuscular
benzathine penicillin 2.4 million units on day 0, 7, 14.
With the patient’s consent an ART with DTG (Tivicay®)
and tenofovir disaproxil fumarate/emtricitabine (TDF/
FTC - Truvada®) was initiated immediately.
His medical history includes an allergic bronchial
asthma, which is treated with ipratropium bromide and
fenoterol hydrobromide. The patient reported on request
occasional cocaine consumption (recreational drug abuse).
On day of admission, the patient reports to have taken
15–20 pills of TDF/FTC and the same amount of DTG,is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain









Figure 1 Course of serum-creatinine concentration starting two
months prior to intoxication, day of intoxication and follow up
period. The transient elevation of serum creatinine five days after
intoxication and the following normalization are demonstrated.
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FTC and 1000 mg DTG in suicidal intention. He admit-
ted having combined the ART overdose with an un-
known amount of vodka and cocaine. Exact time of
ingestion was unclear but most likely within the past
4 hours prior to admission. Physical examination re-
vealed minor airway obstruction; the remaining examin-
ation was without pathological findings. The patient did
not specify any complaints. He was hospitalized and
monitored for 6 hours on our intensive care unit. Within
that period of time, no adverse events occurred, no spe-
cific therapy was necessary.
Upon admission a serum sample was routinely taken.
Blood analysis revealed a minimal TSH-elevation while
normal free thyroid hormons were documented (TSH
4.30 μIU/ml, fT3 4.0 pg/ml, fT4 1.4 ng/ml) (Norm: TSH
0.27 – 4.2 μIU/ml, fT3: 2.00 – 4.30 pg/ml, fT4: 0.90 –
1.90 ng/ml), which was discussed as latent hypothyroidism
formally. The remaining parameters showed no patho-
logical findings. Electrocardiographic analysis showed no
pathological findings, especially QTc time was normal.
DTG concentration in serum sample was 10,013 ng/ml
(norm: > 500 ng/ml). To date, the analyzing lab did not
establish upper limits, however the IC90 for DTG is
64 ng/ml [7], and the mean plasma concentration from
102 samples acquired from 65 patients analyzed in our lab
was 2,226 ng/ml (+/−1,693 ng/ml). These data justify the
conclusion that there was a relevant overdosing in our pa-
tient, measured approximately 4 hours after ingestion.
Toxicological analysis revealed an ethanol concentration
of 0.48 g/l. Intracellular TDF- and FTC-levels could not
be monitored, because no cell fraction sample was stored
at time of admission. Creatinine concentration on admis-
sion was 0.8 mg/dl (70.72 μmol/l) (range: 0.5 – 1.3 mg/dl;
44.2 – 114.92 μmol/l). Five days after ingestion, creatinine
concentration increased 50 % to 1.2 mg/dl (106.08 μmol/L),
however, the parameter never exceeded the pathologic
threshold. Subsequent analysis of serum creatinine eight
weeks later revealed slight reduction to 1.1 mg/dl
(97.24 μmol/l), analysis 12 weeks later revealed further re-
duction of serum levels to 0.9 mg/dl (79.56 μmol/l), repre-
senting his baseline serum creatinine. (Figure 1) No
evidence for any proteinuria or Fanconi syndrome was ob-
served during observation’s period.
The patient was discharged after uneventful monitor-
ing from the hospital without any symptoms and TDF/
FTC + DTG ART was continued without any changes.
He was followed up in the HIV outpatient center and
psychiatric therapy was offered.
Conclusion
Our case of a 21-year old HIV-patient ingesting an over-
dose of DTG and TDF/FTC in suicidal intention sug-
gests a broad safety range of the above mentioned HIVdrugs in the overdose setting of an otherwise healthy pa-
tient. As has been reported, DTG is a potent inhibitor of
the renal transporter OCT2 with creatinine accumula-
tion resulting from that effect [5,8]. In combination with
the potential nephrotoxic TDF, this could lead to im-
paired renal function in case of overdose with one or
both drugs. To the best of our knowledge, additional ef-
fects of TDF overdose or TDF and DTG overdose with
possible implications on renal function of both drugs
have not been reported so far [9]. However, previous
studies demonstrated that the elevation of creatinine fol-
lowing DTG ingestion is not a consequence of reduction
in renal blood flow or renal creatinine clearance (i.e. no
nephrotoxic effect), but is rather directly attributable to
the inhibition of OCT2. This effect was found to be re-
versible [10].
The clinical course of our patient, showing an increase
in creatinine baseline levels of 50% within the first five
days after ingestion, but recovering to previous levels after
the acute event, support the current safety data of DTG
leading to an intermittent increase in serum creatinine.
No permanent impairment in renal function remained in
our case.
In conclusion, DTG over dosage does not seem to lead
to sustained nephrotoxic effects in our case, which sup-
ports the previous study findings of the favorable safety
profile of the drug. Further data from routine clinical
Lee et al. AIDS Research and Therapy  (2015) 12:18 Page 3 of 3use and safety studies are needed to confirm these find-
ings in case of DTG overdose.
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